Medical/Pharmaceuticals
Sirtex Medical's SIR-Spheres® Y-90 Resin Microspheres Receive FDA Approval for the Treatment of Unresectable Hepatocellular Carcinoma
Expanded indication makes SIR-Spheres® the first and only radioembolization therapy in the U.S. approved to treat both unresectable hepatocellular carcinoma and metastatic colorectal cancer WOBURN, Mass., July 7, 2025 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of intervent...
2025-07-07 21:00
2509
WuXi AppTec Receives MSCI ESG AAA Leader Rating
SHANGHAI, July 7, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced it has achieved the AAA rating – the highest level – from MSCI in its lates...
2025-07-07 20:08
1931
Coreline Soft and Temple Health to Co-Host Webinar on AI-Driven Lung Cancer Screening and Improving Patient Outcomes
* Real-world outcomes: How AI improved both diagnostic efficiency, early
detection, and comorbidity detection
* Deep dive into the precision technology of the FDA-cleared platform, AVIEW
LCS Plus PHILADELPHIA and SEOUL, South Korea, July 7, 2025 /PRNewswire/ --
Coreline Soft
2025-07-07 20:00
1955
The Voices of Persons Affected by Hansen's Disease Move the World: 3rd Global Forum Held in Bali, Indonesia
TOKYO, July 7, 2025 /PRNewswire/ -- In a landmark gathering that placed lived experience at the center of global health discourse, the 3rd Global Forum of People's Organizations on Hansen's Disease was held inBali, Indonesia, from July 4 to 6, 2025. Organized by the Sasakawa Leprosy (Hansen's Dis...
2025-07-07 19:00
1589
Nuevocor Strengthens Board with Appointment of Thierry Abribat
SINGAPORE, July 7, 2025 /PRNewswire/ -- Nuevocor
2025-07-07 13:00
1557
DoH, USCF and IGI Explore Establishing the World's first-of-their kind Centres for Genome Surgery
On the sidelines of a high-level U.S. visit ABU DHABI, UAE, July 4, 2025 /PRNewswire/ -- The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, has announced a landmark partnership with the University of California, San Francisco (UCSF) and the Innovati...
2025-07-04 22:43
3254
ESG | HitGen Releases Its Inaugural Sustainability Report
CHENGDU, China, July 4, 2025 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) today announced the release of its inaugural sustainability report, aiming to present the company's philosophies and policies in environmental, social, and governance ("ESG")...
2025-07-04 19:00
4525
Everest Medicines Showcases Breakthroughs in Proprietary AI-Powered mRNA Platform at 2025 R&D Day Held in Shanghai
SHANGHAI, July 4, 2025 /PRNewswire/ -- Everest Medicines (HKEX: 1952.HK), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative medicines, recently hosted the "2025 Everest Medicines mRNA Platform R&D Day" in Shanghai. The e...
2025-07-04 16:58
3312
Kexing Biopharm Makes Its Debut at CPHI 2025, Followed by the 2025 International Pharmaceutical Cooperation High-End Forum, One of the Kexing Biopharm's Series of Globalization Activities in Shanghai
SHENZHEN, China, July 4, 2025 /PRNewswire/ -- Recently, Kexing Biopharm made a remarkable appearance at CPHI & PMEC China 2025 and successfully organized the 2025 International Pharmaceutical Cooperation High-End Forum, one of the Kexing Biopharm's series of globalization activities in Shanghai. ...
2025-07-04 16:26
4120
Brii Biosciences Announces Licensing Agreement with Joincare Group for Rights to BRII-693 in Greater China
* Joincare Group to lead the clinical development and commercialization of BRII-693 in Greater China * Brii Biosciences retains ex-Greater China rights to address the global antimicrobial resistance threats and continues investment in other priority pipeline assets DURHAM, N.C. and BEIJING, J...
2025-07-04 08:30
3590
ReCerf Receives its CE Mark, Advancing Access to Ceramic Hip Resurfacing Across Europe
LEATHERHEAD, England, July 4, 2025 /PRNewswire/ -- MatOrtho® is proud to announce that the ReCerf® Hip Resurfacing Arthroplasty (HRA) has received its CE mark, confirming compliance with European safety and performance standards. This important milestone expands access to hip resurfacing, enablin...
2025-07-04 07:01
2160
NECC Selects MedMinder to Transform Their Medication Management for Individuals with Autism They Serve
NORWOOD, Mass., July 3, 2025 /PRNewswire/ -- The New England Center for Children (NECC), a globally recognized leader in autism education and research, has contracted with MedMinder, to enhance the safety, consistency, and reliability of medication management across its programs. The collaborati...
2025-07-04 01:52
2078
Fangzhou Tops China's App Store Chart for Healthcare Apps
GUANGZHOU, China, July 3, 2025 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in Internet healthcare solutions, earned the top spot in theJune 2025 China AppStore Healthcare TOP100 Free APP Rankings with its Fangzhou Online Pharmacy App, according to a report by ...
2025-07-03 18:43
2268
MOTE Therapeutics Taps MaryJane Rafii as Chief Investment & Business Officer to Drive Global Growth of RNA Delivery Platform
BOSTON, July 3, 2025 /PRNewswire/ -- MOTE Therapeutics (referred as MOTE), a seed-stage biotech developing targeted RNA delivery solutions, announced the appointment ofMaryJane Rafii, PhD, MBA, as Chief Investment and Business Officer. The move comes as MOTE accelerates development of its MOBILIZ...
2025-07-03 18:07
2221
Esaote presents at ECVS 2025 the new generation of veterinary MRI, Vet -MR Grande ELITE
GENOA, Italy and ANTWERP, Belgium, July 3, 2025 /PRNewswire/ -- Esaote, a leading company in the field of medical diagnostic imaging, presents the new Vet -MR Grande ELITE, the next generation of veterinary MRIat the ECVS 2025, the Annual scientific meeting of European College of Veterinary Surge...
2025-07-03 18:00
2736
Akeso's First Bispecific ADC (Trop2/Nectin4 ADC) Enters Clinical Trials, Strengthening Leadership in 'IO+ADC' 2.0 Strategy
HONG KONG, July 3, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") has announced the successful enrollment of the first patient in its Phase Ia clinical trial for AK146D1, a bispecific Antibody-Drug Conjugate (ADC) targeting Trop2 and Nectin4. AK146D1 is Akeso's first bispec...
2025-07-03 14:46
2416
Novotech Earns Frost & Sullivan's 2025 Global Company of the Year Recognition for Excellence in Biotech Clinical Research Services
Recognized for its biotech-first focus, innovation in clinical trial delivery, and best-in-class client experience, Novotech sets the global standard in contract research for biotechs and small- mid-size pharma companies. SAN ANTONIO, July 3, 2025 /PRNewswire/ -- Frost & Sullivan is pleased to a...
2025-07-03 13:30
2196
Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
* ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins * Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningfulbenefits to patien...
2025-07-03 08:08
2299
Neurizon Enters into Global License with Elanco to Accelerate Commercialisation of NUZ-001
Highlights: * Neurizon® Therapeutics and Elanco Animal Health enter into an exclusive global licensing agreement * Provides worldwide rights for Neurizon to utilise Elanco's intellectual property, providing exclusive access to an extensive package of non-clinical studies and manufacturing da...
2025-07-03 07:09
2337
Ascletis Announces First Participants with Obesity or Overweight Dosed in a U.S. 13-week Phase IIa Study of Small Molecule Oral GLP-1R Agonist ASC30
- First participants with obesity or overweight with at least one weight-r elatedcomorbidity have been dosed in a U.S. 13-week Phase IIa study of small m oleculeoral GLP-1 receptor agonist ASC30. - ASC30 oral once-daily tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction f...
2025-07-03 07:00
2232
Week's Top Stories
Most Reposted
Never Miss a Message: Agoda's Customer Support Now Travels With You
[Picked up by 328 media titles]
2026-02-24 12:00
NextFin Asia: A New Dedicated Fund for the Catapult: Inclusion SE Asia Program to Further Scale Inclusive Finance Fintechs in ASEAN
[Picked up by 311 media titles]
2026-02-23 08:00
Amadeus acquires SkyLink to accelerate the deployment of AI in travel
[Picked up by 310 media titles]
2026-02-26 19:57
HBX Group and Traveloka expand strategic partnership to deepen APAC supply and accelerate global distribution
[Picked up by 309 media titles]
2026-02-26 09:30
Klook and Osaka Convention & Tourism Bureau sign MoU to advance inbound tourism and foster socio-economic development throughout Osaka Prefecture
[Picked up by 302 media titles]
2026-02-24 16:13
Most Read
NYSE Content Update: AI Data Platform DDN Appoints Guido Torrini as Finance Chief
2026-02-24 22:08
5746
